Joyo Pharma has secured over 300 million yuan ($46 million) in its Series B round while OrbiMed Healthcare Fund Management has led the $40-million Series B funding in Zion Pharma.
Joyo Pharma nabs over $46m in Series B
Innovative drugs maker Joyo Pharma on Wednesday announced that it has bagged over 300 million yuan ($46 million) in its Series B round jointly led by Sequoia Capital China and state-owned SDIC Venture Capital.
